The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China

医学 赛马鲁肽 成本效益分析 二甲双胍 成本-效用分析 经济评价 质量调整寿命年 2型糖尿病 成本效益 糖尿病 重症监护医学 2型糖尿病 内分泌学 利拉鲁肽 风险分析(工程) 病理
作者
Sihua Wang,Duncong Fan,Qinhong Yao,Xiaojie Sun
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:27 (9): 5269-5279 被引量:3
标识
DOI:10.1111/dom.16580
摘要

AIM: To evaluate the long-term economic implications and potential budgetary consequences for the national health insurance system (NHIS) of tirzepatide versus semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) in China. METHODS: The demographic and clinical efficacy data were derived from the SURPASS-2 trial. The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs). Sensitivity analyses were employed to investigate the presence of uncertainty. The financial implications for the relevant budgetary authority over 5 years were estimated. RESULTS: In the long-term treatment simulation, tirzepatide 5 and 10 mg yielded incremental QALYs of 0.05 and 0.09, in comparison with semaglutide 1 mg, respectively. The associated incremental costs for these treatments were $23 563.42 and $47 583.74, respectively. Consequently, the incremental cost-utility ratios were calculated to be $445 125.24/QALY and $543 829.19/QALY, both of which exceeded the established threshold of $29 599.90/QALY. These base-case results were validated through robust sensitivity analyses. The budget impact analysis showed that such an expansion would incur an additional budgetary burden of approximately $80 million to $490 million for the NHIS over a simulated 5-year period. CONCLUSION: This dual analysis provides policymakers and payers with a comprehensive basis for decision-making. Tirzepatide offered substantial long-term health benefits, but they were not cost-effective compared with semaglutide 1 mg in T2DM patients inadequately controlled with metformin under China's health care providers' perspective. The entry of tirzepatide 5 mg into the NHIS may increase the financial burden of national medical insurance, but overall health care expenditures are expected to decrease, driven primarily by significantly reduced out-of-pocket expenses for patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星仙人掌完成签到 ,获得积分10
1秒前
范梦丽完成签到,获得积分10
1秒前
Camellia发布了新的文献求助10
2秒前
2秒前
科目三的应助被情苏采纳,获得10
2秒前
完美世界的应助被情苏采纳,获得10
3秒前
3秒前
汉堡包的应助被情苏采纳,获得10
3秒前
南楠发布了新的文献求助10
3秒前
3秒前
Jun的应助被情苏采纳,获得10
3秒前
haimianbaobao发布了新的文献求助100
3秒前
科研小哥的应助被情苏采纳,获得30
3秒前
山东科技李发布了新的文献求助100
3秒前
cdercder的应助被情苏采纳,获得10
3秒前
科目三的应助被情苏采纳,获得10
4秒前
科研通AI6.3的应助被情苏采纳,获得10
4秒前
脑子一点儿不转吗完成签到,获得积分10
4秒前
GQ完成签到 ,获得积分10
4秒前
觞酌的应助被渣七采纳,获得10
4秒前
科研通AI6.2的应助被情苏采纳,获得10
4秒前
科研通AI6.3的应助被情苏采纳,获得10
4秒前
5秒前
畅快珩发布了新的文献求助10
6秒前
等待蓝天发布了新的文献求助10
7秒前
陌小千完成签到 ,获得积分0
8秒前
8秒前
JuliusFifthZ完成签到,获得积分10
8秒前
8秒前
聪慧若风发布了新的文献求助10
8秒前
噜噜噜完成签到 ,获得积分10
9秒前
lanlan完成签到,获得积分10
9秒前
传奇3的应助被sx采纳,获得10
9秒前
ccmow完成签到,获得积分10
10秒前
lyt123456发布了新的文献求助10
11秒前
11秒前
Lee完成签到,获得积分10
12秒前
小蘑菇的应助被诚心的志泽采纳,获得10
12秒前
细腻谷南完成签到,获得积分10
12秒前
Heinrich完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565